CoChat

Long-term safety and maintenance of response with esketamine nasal spray in participants with treatment-resistant depression: interim results of the SUSTAIN-3 study

Open access

The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index; 9 of the 30 sources its claims cite were checked for support.

Abstract

Patients with treatment-resistant depression (TRD) have higher rates of relapse and pronounced decreases in daily functioning and health-related quality of life compared to patients with major depressive disorder who are not treatment-resistant, underscoring the need for treatment choices with sustained efficacy and long-term tolerability. Adults with TRD who participated in ≥1 of 6 phase 3 “parent” studies could continue esketamine treatment, combined with an oral antidepressant, by enrolling in phase 3, open-label, long-term extension study, SUSTAIN-3. Based on their status at parent-study end, eligible participants entered a 4-week induction phase followed by an optimization/maintenance phase, or directly entered the optimization/maintenance phase of SUSTAIN-3. Intranasal esketamine dosing was flexible, twice-weekly during induction and individualized to depression severity during optimization/maintenance. At the interim data cutoff (01 December 2020), 1148 participants were enrolled, 458 at induction and 690 at optimization/maintenance. Mean (median) cumulative duration of maintenance esketamine treatment was 31.5 (37.7) months (totaling 2769 cumulative patient-years). Common treatment-emergent adverse events (≥20%) were headache, dizziness, nausea, dissociation, somnolence, and nasopharyngitis. Mean Montgomery–Åsberg Depression Rating Scale (MADRS) total score decreased during induction, and this reduction persisted during optimization/maintenance (mean [SD] change from the baseline to the endpoint of each phase: induction −12.8 [9.73]; optimization/maintenance +1.1 [9.93]), with 35.6% and 46.1% of participants in remission (MADRS total score ≤12) at induction and optimization/maintenance endpoints, respectively. Improvement in depression ratings generally persisted among participants who remained in maintenance treatment, and no new safety signal was identified during long-term treatment (up to 4.5 years) using intermittent-dosed esketamine in conjunction with daily antidepressant.

Overview

CoChat Summary

TL;DR

In this interim analysis of the phase 3 SUSTAIN-3 long-term extension, esketamine nasal spray plus an oral antidepressant was associated with sustained improvement in depressive symptoms and no new safety signal in adults with treatment-resistant depression followed for up to 4.5 years. Common adverse events were mostly mild/moderate and transient, with headache, dizziness, nausea, dissociation, somnolence, and nasopharyngitis among the most frequent.

Key findings

  • Among 1148 enrolled participants, mean (median) cumulative maintenance esketamine exposure was 31.5 (37.7) months, totaling 2769 cumulative patient-years; 81.0% were exposed ≥12 months and 48.4% ≥36 months.
  • MADRS total score decreased during induction (mean [SD] change −12.8 [9.73]) and remained stable during optimization/maintenance (+1.1 [9.93]); remission (MADRS ≤12) was 35.6% at induction endpoint and 46.1% at optimization/maintenance endpoint.
  • Common treatment-emergent adverse events (≥20%) were headache, dizziness, nausea, dissociation, somnolence, and nasopharyngitis; 96.8% of adverse events were mild or moderate, and 5.8% discontinued study drug due to adverse events.
  • No new safety signal was identified; no psychosis was reported, no treatment-related interstitial/ulcerative cystitis was identified, and serious adverse events were reported in 14.9% of participants, with 5 deaths (0.4%) none considered related to esketamine.

Methods

  • Phase 3, open-label, multicenter (n = 59), long-term extension study of adults with treatment-resistant depression who had participated in ≥1 of 6 phase 3 parent studies; participants entered a 4-week induction phase or directly entered optimization/maintenance based on parent-study status.
  • Esketamine nasal spray was self-administered under medical supervision at flexible doses (28 mg for age ≥65 years, 56 mg, or 84 mg) twice weekly during induction and individualized to depression severity during optimization/maintenance, combined with an investigator-prescribed oral antidepressant.
  • Safety and efficacy were summarized descriptively at an interim data cutoff of 01 December 2020; assessments included treatment-emergent adverse events, MADRS, PHQ-9, CGI-S, SDS, C-SSRS, cognitive testing, and vital signs.

Limitations

  • The paper states that generalizability is limited by potential bias related to which participants chose to continue from parent studies, exclusion of participants with significant psychiatric or medical comorbidities or substance dependence, and limited racial heterogeneity (86.8% white); sample size decreased at later time points, and the data are interim and continue to be updated.
  • The paper notes that without a placebo group it is difficult to determine to what extent slowing of reaction time in participants ≥65 years reflects study drug, and that ketamine abuse could not have been detected if participants obtained illicit drug because the urine drug screen did not assay for the r-enantiomer of ketamine or its metabolites.
  • Evident from the text: the study is open-label, so efficacy findings may be influenced by lack of blinding and no randomized comparator during long-term treatment.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1038/s41386-023-01577-5

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 SUSTAIN-3 Participant Disposition. aOne each: scheduling conflicts; multiple reasons (mainly, feeling better, wanted to start working again, adverse events, and time requirements of study); withdrew consent; participant’s choice despite investigator’s advice to continue; relocation; and death on study day 26 due to completed suicide, 4 days after the last dose of esketamine. bOther reasons (each ≤1%, e.g., investigator/sponsor decision, employment/school, personal reasons, death [4 participants, as described in Supplementary Material]). Note: Participants were eligible to enroll into the Induction Phase or the Optimization/Maintenance Phase based on their status at the end of the parent study (refer to Table S2). Participants received open-label esketamine nasal spray (28 mg [only an option for participants ≥65 years], 56 mg, or 84 mg) twice per week during the Induction Phase, and weekly, every other week, or every 4 weeks, based on clinical global impression - severity (CGI-S) and tolerability, during the Optimization/Maintenance Phase.
Fig. 1 SUSTAIN-3 Participant Disposition. aOne each: scheduling conflicts; multiple reasons (mainly, feeling better, wanted to start working again, adverse events, and time requirements of study); withdrew consent; participant’s choice despite investigator’s advice to continue; relocation; and death on study day 26 due to completed suicide, 4 days after the last dose of esketamine. bOther reasons (each ≤1%, e.g., investigator/sponsor decision, employment/school, personal reasons, death [4 participants, as described in Supplementary Material]). Note: Participants were eligible to enroll into the Induction Phase or the Optimization/Maintenance Phase based on their status at the end of the parent study (refer to Table S2). Participants received open-label esketamine nasal spray (28 mg [only an option for participants ≥65 years], 56 mg, or 84 mg) twice per week during the Induction Phase, and weekly, every other week, or every 4 weeks, based on clinical global impression - severity (CGI-S) and tolerability, during the Optimization/Maintenance Phase.CC BY · PubMed Central
Fig. 2 Mean (±SE) Montgomery–Åsberg Depression Rating Scale Total Score (Observed Cases). IND Induction, OP/MA optimization/Maintenance. Note: Responders from the induction phase of the SUSTAIN-3 study and responders from parent studies were to enter the optimization/maintenance phase. The greater variability of the mean MADRS total score at later time points likely reflects the smaller number of participants at these timepoints, as reflected in the corresponding sample sizes.
Fig. 2 Mean (±SE) Montgomery–Åsberg Depression Rating Scale Total Score (Observed Cases). IND Induction, OP/MA optimization/Maintenance. Note: Responders from the induction phase of the SUSTAIN-3 study and responders from parent studies were to enter the optimization/maintenance phase. The greater variability of the mean MADRS total score at later time points likely reflects the smaller number of participants at these timepoints, as reflected in the corresponding sample sizes.CC BY · PubMed Central
Fig. 3 Clinical global impression–severity (CGI-S): frequency distribution over time. a Induction Phase. b Optimization/Maintenance Phase. Notes: Every-8-week data are presented. The visits with fewer than 10 participants are not presented. The CGI-S evaluates the severity of psychopathology on a scale of 1 to 7: 1 = normal (not at all ill); 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; 7 = among the most extremely ill patients.
Fig. 3 Clinical global impression–severity (CGI-S): frequency distribution over time. a Induction Phase. b Optimization/Maintenance Phase. Notes: Every-8-week data are presented. The visits with fewer than 10 participants are not presented. The CGI-S evaluates the severity of psychopathology on a scale of 1 to 7: 1 = normal (not at all ill); 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; 7 = among the most extremely ill patients.CC BY · PubMed Central

Verification

Claims the paper makes

4 Valid · 0 Not valid · 12 Not checked · 106 Own results and interpretations

70 more claims

Create a free account to see all 122 claims and to verify the 21 references still open.

See all claims — free account
  • It may state two separate claims as one. 40
  • Probably not a substantial claim. 12

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

1 of 1

Citations

Cites

Show all 31 references

Cited by

See all 137

Metadata

Authors
Zaki, N., Chen, L., Lane, R., Doherty, T., Drevets, W. C., Morrison, R. L., Sanacora, G., Wilkinson, S. T., Popova, V., & Fu, D.-J.
Affiliations
  • Janssen Research & Development (United States) (US)
  • Janssen (United States) (US)
  • Yale University (US)
  • Janssen (Belgium) (BE)
Corresponding author
Zaki, Naim
Venue
Neuropsychopharmacology
Published
2023-05-12
Volume
48
Issue
8
Pages
1225-1233
ISSN
  • 0893-133X (ISSN-L)
  • 1740-634X
OpenAlex
W4376274076
Cited by
137
References
31
Citations by year
2026: 35 · 2025: 46 · 2024: 41 · 2023: 15
FWCI
21.16
Type
journal article
Language
en
Open access
Licence
Locations
  • Neuropsychopharmacology (publishedVersion, cc-by)
  • FOCUS The Journal of Lifelong Learning in Psychiatry (publishedVersion)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • PubMed Central (publishedVersion)
Funders
  • Janssen Research & Development LLC, Titusville, NJ USA
  • Janssen Research & Development, LLC, Titusville, NJ, US
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
  • Life Sciences › Neuroscience › Neurology › Transcranial Magnetic Stimulation Studies
Keywords
esketamine, treatment-resistant depression, long-term maintenance therapy, long-term tolerability, relapse prevention, intermittent dosing, treatment-emergent adverse events, depression remission
MeSH terms
Adult, Antidepressive Agents, Depression, Major Depressive Disorder, Double-Blind Method, Humans, Ketamine, Quality of Life, Treatment Outcome, Nasal Sprays, Depressive Disorder, Treatment-Resistant

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Long-term safety and maintenance of response with esketamine nasal spray in participants with treatment-resistant depression: interim results of the SUSTAIN-3 study. https://app.cochat.ai/papers/10.1038/s41386-023-01577-5
The paper
Zaki, N., Chen, L., Lane, R., Doherty, T., Drevets, W. C., Morrison, R. L., Sanacora, G., Wilkinson, S. T., Popova, V., & Fu, D.-J. (2023). Long-term safety and maintenance of response with esketamine nasal spray in participants with treatment-resistant depression: interim results of the SUSTAIN-3 study. Neuropsychopharmacology. https://doi.org/10.1038/s41386-023-01577-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.